ClinicalTrials.gg
CompletedNCT01053962CICUpdated Jan 2, 2020Results posted

SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation

A Phase 2 interventional study of SP-304 0.3 mg and SP-304 1.0 mg in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-01-02.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.

Enrollment
12th of 12
84 · median 800
Started
2010
the only one that year
Phase 2
5 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
11 of 12
Bausch Health Americas, Inc.

Among the 12 studies testing plecanatide in Constipation, this one is the 12th largest by enrollment, is the only one that started in 2010, is one of 5 in phase 2, and was the 1st registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →

Where they have run

About plecanatide

plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing plecanatide in Constipation as a file.
02

Study summary

This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic idiopathic constipation.

Read the detailed description

This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, PK and PD effects of SP-304 in patients with chronic idiopathic constipation. Patients diagnosed with chronic idiopathic constipation (CIC) will be screened for the anticipated 4 cohorts, to yield 80 randomized patients for enrollment. Four dose cohorts are planned (0.3 mg, 1.0 mg, 3.0mg, and 9.0 mg) with 20 patients per dose cohort [randomization ratio 3:1 (15 receive SP-304:5 receive placebo)]. Patients who continue to meet all the entry criteria and complete the pre-treatment bowel movement (BM) diary will receive, in a double-blind, randomized fashion, SP-304 or matching placebo. It is expected that each patient will complete all 14 days of dosing (including making accurate BM diary entries for all 14 days in the treatment period). All patients receiving at least one dose of SP-304 or matching placebo will be considered evaluable for the safety endpoints. If a patient receives at least 5 doses per treatment week (1 dose per day for 7 days) and has completed BM diary entries for those 5 dosing days in each corresponding treatment week, he/she will be considered evaluable.

03

Conditions studied

  • Chronic Idiopathic Constipation

Keywords

  • Chronic Idiopathic Constipation
  • Constipation
  • Irritable Bowel Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is able to understand and willing to sign the Form (ICF) and capable of providing written authorization for use and disclosure of protected health information per requirements of 45 CFR 164.508 (Health Insurance Portability and Accountability Act [HIPAA]).
  • Subject is male or non-pregnant, non-breastfeeding female, between 18 and 75 years of age (inclusive) at the time of first dose.
  • Subject has a (BMI) between 18 and 35 kg/m2.
  • Subject meets the Rome III Diagnostic Criteria for constipation (Drossman, 2006) for the past 3 months with symptom onset > 6 months prior to diagnosis.

Exclusion criteria

Exclusion Criteria:

  • Subject reports loose stool (fluffy pieces with ragged edges, a mushy stool) or watery stool (no solid pieces, entirely liquid; BSFS score of 6 or 7, respectively) in the absence of any laxative, enema, suppository or prohibited medicine for > 25% of BMs during the 3 months prior to the Screening visit and during the 14 day pre-treatment period.
  • Subjects who meet the Rome III criteria for IBS.
  • Subject has failed to complete the pre-treatment bowel movement diary accurately and completely during the pre-treatment period prior to Day 1 dosing.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    SP-304 0.3 mg

    SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days.

    Drug: SP-304 0.3 mg

  • Experimental
    SP-304 1.0 mg

    SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days.

    Drug: SP-304 1.0 mg

  • Experimental
    SP-304 3.0 mg

    SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days

    Drug: SP-304 3.0 mg

  • Experimental
    SP-304 9.0 mg

    SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days.

    Drug: SP-304 9.0 mg

  • Placebo comparator
    Placebo

    Placebo tablet by mouth once daily for 14 consecutive days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Incidences of adverse events from Baseline through the end of the Follow-up period.

    Time frame: 21 days: Baseline through Follow-up (Treatment Days 14, 7 days post treatment)

Secondary outcomes

  1. Change From Baseline Overall in Number of Complete Spontaneous Bowel Movements (CSBM)

    Using a Daily Diary, patients recorded the number of spontaneous bowel movements having the sensation of complete evacuation (Complete Spontaneous Bowel Movement - CSBM). The total number of spontaneous bowel movements associated with a feeling of complete evacuation were summed and divided by 2 (the number of weeks in treatment). Change was calculated as the difference between the number of the CSBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.

    Time frame: Study days 1 through 14

  2. Change From Baseline Overall in Number of Spontaneous Bowel Movements (SBM)

    Using a Daily Diary, patients recorded the number of spontaneous bowel movements (SBM). The overall weekly frequency was calculated as the total number of SBMs divided by 2 (the number weeks of treatment). Change was calculated as the difference between the number of the SBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.

    Time frame: Study Days 1 through 14

  3. Changes From Baseline Overall in Bristol Stool Form Scale (BSFS)

    Using a Daily Diary, patients recorded Stool Consistency using the 7-point Bristol Stool Form Scale (BSFS) (1 = separate hard lumps, like nuts; 2 sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces, entirely liquid). Changes in mean BSFS were assessed from the average 14-day pretreatment baseline to the average during the 2-week treatment period.

    Time frame: Study day 1 through 14

  4. Changes From Baseline Overall in Ease of Passage (Straining)

    Using a Daily Diary, patients recorded Ease of Passage (Straining) using the 7-point Ease-of-Passage Scale (1 = manual disimpaction/enema needed, 2 = severe straining, 3 = moderate straining, 4 = mild straining, 5 = no straining, 6 = urgency, 7 = incontinent). Changes in overall ease of passage (Straining) were assessed from the average 14-day pretreatment baseline to average during the 2-week treatment period

    Time frame: Study Days 1 through 14

07

Results

Posted Jan 2, 2020
Limitations and caveats
This Phase 2a study was not sized to evaluate efficacy.

Participant flow

This study was conducted between 3 March 2010 and 26 August 2010 at 14 study centers in the United States. Four dose cohorts were planned (0.3 mg, 1.0 mg, 3.0 mg, and 9.0 mg with 20 patients per dose cohort randomized in a 3:1 ratio \[15 pts receive SP-304, 5 pts receive placebo\].

Pretreatment Period
Participant flow — Pretreatment Period
MilestoneSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
Started1415161722
Completed1414151520
Not completed01122
Withdrew: Withdrew consent (patient/pi)00012
Withdrew: Venipuncture failure00100
Withdrew: Failed urine drug screen day 101000
Withdrew: Abnormal lab values exl 1600010
Treatment Period
Participant flow — Treatment Period
MilestoneSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
Started1414151520
Completed1314151517
Not completed10003
Withdrew: Lack of efficacy00001
Withdrew: Adverse event00001
Withdrew: Withdrawal by subject00001
Withdrew: Noncompliance with protocol10000
Follow-up Period
Participant flow — Follow-up Period
MilestoneSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
Started1314151517
Completed1314151517
Not completed00000

Outcome measures

PrimaryNumber of Participants With Adverse Events

Incidences of adverse events from Baseline through the end of the Follow-up period.

Time frame:
21 days: Baseline through Follow-up (Treatment Days 14, 7 days post treatment)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
Number of Participants With Adverse Events36264
SecondaryChange From Baseline Overall in Number of Complete Spontaneous Bowel Movements (CSBM)

Using a Daily Diary, patients recorded the number of spontaneous bowel movements having the sensation of complete evacuation (Complete Spontaneous Bowel Movement - CSBM). The total number of spontaneous bowel movements associated with a feeling of complete evacuation were summed and divided by 2 (the number of weeks in treatment). Change was calculated as the difference between the number of the CSBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.

Time frame:
Study days 1 through 14
Reported as:
Mean · CSBMs per week
Change From Baseline Overall in Number of Complete Spontaneous Bowel Movements (CSBM)
CSBMs per weekSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
Change From Baseline Overall in Number of Complete Spontaneous Bowel Movements (CSBM)1.7 ± 2.303.3 ± 2.851.8 ± 3.752.7 ± 2.892.0 ± 3.02
SecondaryChange From Baseline Overall in Number of Spontaneous Bowel Movements (SBM)

Using a Daily Diary, patients recorded the number of spontaneous bowel movements (SBM). The overall weekly frequency was calculated as the total number of SBMs divided by 2 (the number weeks of treatment). Change was calculated as the difference between the number of the SBMs at the completion of the 2-week treatment period, versus the 14-day pretreatment baseline.

Time frame:
Study Days 1 through 14
Reported as:
Mean · SBMs per week
Change From Baseline Overall in Number of Spontaneous Bowel Movements (SBM)
SBMs per weekSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
Change From Baseline Overall in Number of Spontaneous Bowel Movements (SBM)2.4 ± 2.214.1 ± 4.12.4 ± 3.394.2 ± 2.882.4 ± 2.67
SecondaryChanges From Baseline Overall in Bristol Stool Form Scale (BSFS)

Using a Daily Diary, patients recorded Stool Consistency using the 7-point Bristol Stool Form Scale (BSFS) (1 = separate hard lumps, like nuts; 2 sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges; 6 = fluffy pieces with ragged edges, a mushy stool; 7 = watery, no solid pieces, entirely liquid). Changes in mean BSFS were assessed from the average 14-day pretreatment baseline to the average during the 2-week treatment period.

Time frame:
Study day 1 through 14
Reported as:
Mean · units on a scale
Changes From Baseline Overall in Bristol Stool Form Scale (BSFS)
units on a scaleSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
Changes From Baseline Overall in Bristol Stool Form Scale (BSFS)1.1 ± 1.231.8 ± 1.181.6 ± 1.531.8 ± 1.560.9 ± 1.23
SecondaryChanges From Baseline Overall in Ease of Passage (Straining)

Using a Daily Diary, patients recorded Ease of Passage (Straining) using the 7-point Ease-of-Passage Scale (1 = manual disimpaction/enema needed, 2 = severe straining, 3 = moderate straining, 4 = mild straining, 5 = no straining, 6 = urgency, 7 = incontinent). Changes in overall ease of passage (Straining) were assessed from the average 14-day pretreatment baseline to average during the 2-week treatment period

Time frame:
Study Days 1 through 14
Reported as:
Mean · units on a scale
Changes From Baseline Overall in Ease of Passage (Straining)
units on a scaleSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
Changes From Baseline Overall in Ease of Passage (Straining)0.9 ± 1.051.6 ± 1.041.3 ± 1.171.2 ± 1.060.5 ± 1.12

Adverse events

Collected over 21 Days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SP-304 0.3 mg—0/14 (0%)3/14 (21.4%)
SP-304 1.0 mg—0/14 (0%)6/14 (42.9%)
SP-304 3.0 mg—0/15 (0%)2/15 (13.3%)
SP-304 9.0 mg—0/15 (0%)6/15 (40%)
Placebo—1/20 (5%)4/20 (20%)
Most frequent serious events
Most frequent serious events
EventSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
PyelonephritisRenal and urinary disorders0/140/140/150/151/20
Most frequent other events
Showing 10 of 30
Most frequent other events
EventSP-304 0.3 mgSP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlacebo
Elevated LipaseInvestigations0/142/141/151/150/20
HeadacheNervous system disorders1/140/140/152/150/20
HyperglycemiaEndocrine disorders0/141/140/150/150/20
GastritisGastrointestinal disorders1/140/140/150/150/20
Hiatus HerniaGastrointestinal disorders1/140/140/150/150/20
NauseaGastrointestinal disorders1/140/140/150/150/20
TirednessGeneral disorders0/141/140/150/150/20
Elevated AmylaseInvestigations1/140/140/150/150/20
Back PainMusculoskeletal and connective tissue disorders0/141/140/150/150/20
Intermittent Right Hand PainMusculoskeletal and connective tissue disorders0/141/140/150/150/20

Baseline characteristics

Safety Population: patients who received at least one dose of study medication (population for primary endpoint).

Age, Categorical
Age, Categorical(Participants)SP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlaceboSP-304 0.3 mgTotal
<=18 years000000
Between 18 and 65 years121114171165
>=65 years2413313
Age, Continuous
Age, Continuous(years)SP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlaceboSP-304 0.3 mgTotal
Mean50.5 ± 10.648.5 ± 16.1747.3 ± 12.7147.7 ± 14.6451.1 ± 11.9548.9 ± 13.24
Sex: Female, Male
Sex: Female, Male(Participants)SP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlaceboSP-304 0.3 mgTotal
Female141312181269
Male023229
Region of Enrollment
Region of Enrollment(participants)SP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlaceboSP-304 0.3 mgTotal
United States141515201478
Complete Spontaneous Bowel Movement Frequency
Complete Spontaneous Bowel Movement Frequency(CSBMs per week)SP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlaceboSP-304 0.3 mgTotal
Mean0.6 ± 0.740.5 ± 0.920.4 ± 0.540.3 ± 0.530.4 ± 0.530.4 ± 0.66
Spontaneous Bowel Movement Frequency
Spontaneous Bowel Movement Frequency(events per week)SP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlaceboSP-304 0.3 mgTotal
Mean2.2 ± 0.992.1 ± 0.931.9 ± 0.752.0 ± 1.012.2 ± 1.122.1 ± 0.95
Stool Consistency (Bristol Stool Form Scale)
Stool Consistency (Bristol Stool Form Scale)(units on a scale)SP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlaceboSP-304 0.3 mgTotal
Mean2.6 ± 0.841.8 ± 0.692.7 ± 1.562.6 ± 1.282.5 ± 0.812.4 ± 1.13
Ease of Passage (Straining)
Ease of Passage (Straining)(units on a scale)SP-304 1.0 mgSP-304 3.0 mgSP-304 9.0 mgPlaceboSP-304 0.3 mgTotal
Mean2.8 ± 0.792.7 ± 0.613.0 ± 0.893.0 ± 0.673.1 ± 0.642.9 ± 0.72
08

Study locations

14 sites
  • Novara Clinical Research
    Mesa, Arizona 85206, United States
  • Genova Clinical Research
    Tucson, Arizona 85741, United States
  • Advanced Clinical Research
    Anaheim, California 92801, United States
  • Advanced Clinical Research
    Orange, California 92869, United States
  • A.G.A. Clinical Trials
    Hialeah, Florida 33012, United States
  • Miami Ressearch and Associates
    Miami, Florida 33143, United States
  • Lee Research Institute
    Shawnee Mission, Kansas 66218, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Universtiy of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Memphis Gastroenterology Group
    Germantown, Tennessee 38138, United States
  • Nashville Medical Research Institute
    Nashville, Tennessee 37205, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Pioneer Research Solutions
    Sugar Land, Texas 77479, United States
09

References and documents

Publications

  • Shailubhai K, Talluto C, Comiskey S, Foss J, Joslyn A, Jacob G. Phase II Clinical Evaluation of SP-304, a Guanylate Cyclase-C Agonist, for Treatment of Chronic Constipation. Am J Gastroenterology 105 (Supp 1): S487, 2010
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 9 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2010
First posted
Jan 22, 2010
Start
Mar 2010
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Results first posted
Jan 2, 2020
Last update
Jan 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01053962
Responsible party
Sponsor
First posted
Jan 22, 2010
Start date
Mar 2010
Primary completion
Aug 2010
Completion
Aug 2010
Results posted
Jan 2, 2020
Last update
Jan 2, 2020

Study contacts

Gary S Jacob, Ph.D.
study director · Synergy Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion